anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Women with pelvic floor disorders (PFDs) typically undergo surgery involving transvaginal mesh implants; however, transvaginal mesh surgery is associated with many adverse events including post-surgical pain. Assessment of pain as a symptom is necessary using patient-reported outcome measures (PROMs). This scoping review aimed to describe and compare existing PROMs previously used to measure pain in women with PFDs. A scoping search of Ovid MEDLINE, EMBASE, CINAHL Plus, Ovid PsycInfo, and grey literature was conducted. Studies published in English describing the development, implementation, and application of PFD-associated pain PROMs among adult women before and after pelvic floor surgery were included. From each article, a descriptive summary organised by study first author, publication year, country, setting, aim, study characteristics, and results were extracted. From 2,604 articles identified, 54 studies were included, describing 44 PROMs. Most studies described at least 2 to 3 instruments. The Pelvic Floor Distress Inventory-20 was most commonly described by 12 studies followed by the Patient Global Impression of Improvement scale. Of the 44 PROMs, 27 were condition-specific, of which 9 included items on pain; 17 generic PROMs, 4 of which contained items on pain; and 6 pain-specific PROMs. PROMs identified in our review measured pain not related to PFDs or pelvic floor surgery and quantified the pain experienced. These PROMs did not measure all areas of pain including region, sensation, impact, and triggers. The findings of this review will assist with developing a new pain-specific PROM in this population. PERSPECTIVE: Women with pelvic floor disorders often undergo surgery involving transvaginal mesh, from which they experience debilitating pain. Pain is a major issue impacting women's lives. Patient-reported outcome measures can be used to assess the pain; however, it is unclear whether existing instruments are relevant.
Long COVID presents with diverse symptoms after COVID-19. Different clusters of symptoms have been reported; however, their persistence beyond 2 years after COVID-19 remains unclear. In this cohort study, we prospectively evaluated individuals with previous severe COVID-19 presenting with long COVID at a two-year follow-up. We characterized the included patients and performed a cluster analysis of symptoms through multiple correspondence analysis and hierarchical clustering. A total of 199 patients with long COVID were included. The median age was 58 years (48-69), 56% were male, and the median follow-up time since the COVID-19 diagnosis was 26 months (IQR: 25, 27). Three symptom clusters were identified: Cluster 1 is characterized by fatigue, myalgia/arthralgia, a low prevalence of symptoms, and a lack of specific symptoms; Cluster 2 is defined by a high prevalence of fatigue, myalgia/arthralgia, and cardiorespiratory symptoms, including palpitations, shortness of breath, cough, and chest pain; and Cluster 3 is demonstrated a high prevalence of ageusia, anosmia, fatigue, and cardiorespiratory symptoms. Our study reinforces the concept of symptom clustering in long COVID, providing evidence that these clusters may persist beyond two years after a COVID-19 diagnosis. This highlights the chronic and debilitating nature of long COVID and the importance of developing strategies to mitigate symptoms in these patients.
A new pharmaceutical composition and the procedure of its preparation are disclosed, useful in the treatment of AIDS of certain viruses and autoimmune diseases and formulated as an aqueous injectable, or orally administered solution. Four examples are given of the pharmaceutical composition according to the invention. Example I: the pharmaceutical composition is composed of the calcium and sodium double salt of ethylenediaminetetraacetic acid, associated with calcium gluconate, reduced glutathione and sodium metabisulfite, wherein the weight ratio of the ingredients ranges from 5-10.5 g to 0.2-2 g to 0.01-0.1 g to 0.01-0.2 g respectively per 100 ml of water. Example II: the calcium disodium salt of ethylenediaminetetraacetic acid associated with calcium gluconate and L-histidine wherein the weight ratio for the active ingredients ranges from 5-10.5 g to 0.3-1 g to 0.05-0.2 g respectively per 100 ml of water. Example III: the calcium and sodium salt of diethylenetriaminepentaacetic acid (DTPA Na3Ca) associated with calcium gluconate, L-cysteine hydrochloride and sodium metabisulfite, the association weight ratio of the ingredients is 5-10 g to 0.4-1 g to 0.03-0.15 g to 0.05-0.15 g respectively per 100 ml water. Example IV: the calcium disodium salt of ethylenediaminetetraacetic acid associated with calcium gluconate, L-cysteine hydrochloride and sodium metabisulfite, wherein the weight ratio of the four active ingredients ranges from 9-11 g to 0.4-0.8 g to 0.1-0.3 g to 0.1-0.3 g respectively per 100 ml of water.
Patients with medically refractory epilepsy who are registering to take CBD in the State of Minnesota will be offered the opportunity to participate in this study. If consent to participation is obtained, the patient (or more likely, the patient's guardian) will be asked to begin a seizure diary for at least a 7-day period prior (ideally, longer) to receiving the CBD, and to continue tracking seizures throughout the study. Upon receipt of CBD from the Minnesota dispensary, subjects will take their CBD as directed and will return to the clinic for a repeat visit (which is part of standard care) occurring 2-8 weeks after continual use of CBD. During these clinic visits, patients undergo blood draws to monitor their other prescribed AED concentrations as part of standard of care. In addition to the standard blood draw, the research participant will be asked to provide a blood sample of 5 ml to measure CBD concentrations. As most patients are instructed to take CBD two hours prior to their standard of care AEDs, clinical experience indicates that most patients are taking CBD quite early in the morning (around 6 AM). Thus, the time of sample collection will be recorded as hours post-dose, and will likely be nearer peak serum concentrations. If a study participant has an indwelling intravenous access port, they will be asked to provide an additional sample of 5 ml at least one hour after the initial sample. During the repeat visit, subjects will be asked to continue documenting seizure activity in their seizure diary while they continue their CBD treatment. Any changes to AEDs administered concurrently with CBD will also be recorded.

Subjects who are already on a stable regimen of CBD will also be eligible to participate. At a clinic visit, they will be asked to provide a blood sample of 5 ml, the time of each sample will be recorded as hours post-dose of CBD. They will also be asked to begin a seizure diary and continue tracking seizure activity. If a patient terminates their CBD treatment, they will be asked to continue tracking seizure activity after their last CBD dose until their follow-up clinic visit, to determine change in seizure activity while on and off CBD.
The invention provides honey-refined Lycium ruthenicum Murr Siwu decoction tea. As Lycium ruthenicum Murr contains 13 trace elements and 17 amino acids, the Siwu decoction tea has efficacy of nourishing liver and kidney, boosting essence and improving eyesight. As four medicinal materials, such as Chinese angelica, ligusticum wallichii, white peony root and radix rehmanniae preparata, are famous blood-enriching prescriptions, the Siwu decoction tea has efficacy of enriching the blood and tonifying qi-blood. By compatibility of Lycium ruthenicum Murr, Chinese angelica, ligusticum wallichii, white peony root and radix rehmanniae preparata, a honey-refined oral thick paste is prepared. A beverage which is convenient to drink, has excellent mouthfeel and can be used as a daily blended beverage is provided. The honey-refined health-preserving tea which has efficacy of maintaining beauty and keeping young, supplementing trace elements and mineral matter and enriching blood and nourishing.
Long-term carcinogenicity studies have not been conducted with lefamulin.

Lefamulin did not elicit genotoxic potential in an in vivo rat bone marrow micronucleus assay for clastogenicity or in the in vitro Mouse Lymphoma Ly5178Y TK+/- mutation assay. The main human metabolite of lefamulin (2R-hydroxy lefamulin) also did not elicit genotoxic potential in the in vitro Mouse Lymphoma Ly5178Y TK+/- mutation assay.

In rats, there were no effects on male fertility that were considered to be related to lefamulin. Reproductive indices including mating behavior and fertility were not changed in any group in either gender at the highest dose tested (75 mg/kg/day, approximately 0.7 times the mean exposure of CABP patients treated IV, based on AUC0-24h); that dose was the NOAEL for fertility in male rats. In females, abnormal estrous cycling and increased post-implantation loss were observed at the high dose, making the NOAEL for fertility and early embryonic development in female rats the next highest dose, 50 mg/kg/day (approximately 0.5 times the mean exposure of CABP patients treated IV).
Age and sex-matched healthy individuals will also be recruited as a control group. They will be scanned three times (baseline, 3-week, and 6-week time points).
This invention provides isolated nucleic acid molecules encoding human 5-HT1D? receptors, isolated proteins which are human 5-HT1D? receptors, vectors comprising isolated nucleic acid molecules encoding human 5-HT1D? receptors, mammalian cells comprising such vectors, antibodies directed to the human 5-HT1D? receptors, nucleic acid probes useful for detecting nucleic acid encoding human 5-HT1D? receptors, antisense oligonucleotides complementary to any sequences of a nucleic acid molecule which encodes a human 5-HT1D? receptor, pharmaceutical compounds related to human 5-HT1D? receptors, and nonhuman transgenic animals which express DNA a normal or a mutant human 5-HT1D? receptor. This invention further provides methods for determining ligand binding, detecting expression, drug screening, and treatment involving the human 5-HT1D? receptor.
INTRODUCTION: Patients affected by metastatic germ cell tumors may occasionally experience enlargement of masses with concurrent normalization of tumor markers during or after chemotherapy. This phenomenon is described as growing teratoma syndrome (GTS). The aim of the pre sent study is to assess the prevalence of GTS in the pediatric population and its implications in terms of surgical outcome.
PATIENTS AND METHODS: The clinical notes of patients diagnosed with stage III and IV malignant germ cell tumors from January 2010 until December 2020 at our Institution were retrospectively reviewed. The prevalence of GTS, treatment strategies, survival, and outcome were analyzed.
RESULTS: Thirty-three patients with high-stage malignant germ cell tumors were diagnosed in our institution in the analyzed period. Nine patients (28%) had radiologic evidence of enlargement of persistent masses with normal markers after chemotherapy; these patients were classified as GTS patients. All nine patients underwent resection of metastatic lymph nodes, and six had surgery on visceral metastases. In six patients, radical excision of all metastatic sites was achieved; five patients are alive and in complete remission, while one died because of peri-operative complications. Out of the three patients who could not achieve radical excision of the metastases, two died of progressive disease, and one is alive with progressive disease.
CONCLUSIONS: Patients affected by GTS have a risk of progression of chemotherapy-resistant disease and death. Radical surgical excision is essential to achieve disease control and long-term survival.
A method of interacting with a patient avatar is provided that includes receiving patient data, including historical health information, for at least one patient at a centralized server system associated with at least one of a clinician device or a. patient device. The method also includes generating the patient avatar based on the patient data. The patient avatar includes a two-dimensional or three-dimensional graphical representation of the patient, with the historical health information displayed as physical characteristics of the patient avatar. The method additionally includes displaying the patient avatar on a graphical user interface associated with at least one of the clinician device or the patient device. The method further includes playing back a graphical representation of a temporal evolution of the patient avatar in response to receiving a playback command. The temporal evolution of the patient avatar includes a change overtime in historical health information of the patient.
Synthetic single stranded RNA molecule(s) and derivatives thereof possessing highly specific endoribonuclease activity, hereindefined as ribozyme. The ribozyme cleaves target RNA sequence by hybridizing partially to the target RNA. It comprises of a hybridizing region and a catalytic region. The hybridizing region contains one or more arms of single stranded RNA. The preferred ribozyme has a catalytic region consisting of the sequence (I), in a loop structure where * represents base pairing between complementary nucleotides, X is any ribonucleotide and N1 and N2 represent ribonucleotides of complementary sequences along at least part of the length. The ribozyme cleaves target RNA after the triplet XUY, where X is any ribonucleotide, U is uracil and Y is adenine, cytosine or uracil. Methods for inactivating RNA (in vitro or in vivo), methods of preparing the ribozymes, and compositions containing the ribozymes are also described.
Tobacco use remains the foremost cause of preventable deaths in the U.S. and worldwide. Advancing new smoking cessation therapies, including those with novel pharmacological targets, is a critical public health priority. The serotonin (5-hydroxtytryptamine; 5-HT) system is broadly implicated in the regulation of reward- related behavior, including drug seeking, in part reflecting its modulatory role in dopamine (DA) function. Recent studies show that targeted manipulation of the serotonin 5-HT2C receptor alters drug-related behavior; in particular, 5-HT2C receptor agonists are shown to reduce nicotine intake and reinstatement. Of the selective 5-HT2C receptor agonists, lorcaserin has the best near-term potential for repurposing as a smoking cessation therapy, having been approved by the U.S. Food and Drug Administration for weight management.

Preclinical findings implicate several potential behavioral mechanisms by which 5-HT2C receptor agonists might reduce drug intake, including drug-specific processes (e.g., incentive salience of drug cues, self-administration, reinstatement) and drug-nonspecific behaviors (e.g., reductions in impulsivity). To date, potential mechanisms of 5-HT2C receptor agonists have not been characterized in human studies. Given emerging interest in lorcaserin as a novel smoking cessation therapy, further studies are needed to evaluate its efficacy profile, including studies to evaluate candidate treatment mechanisms. This human laboratory investigation will examine the effects of lorcaserin vs. placebo on relapse-related outcomes using a double-blind, within-subjects, crossover design. Impulsivity subdomains will also be examined as candidate mechanisms for medication effects. By evaluating an approved 5-HT2C agonist with emergent efficacy for smoking cessation, this project has near-term potential to inform clinical applications of 5-HT2C agonists for addiction.
BACKGROUND: Femur-first (FF) technique for mobile-bearing medial unicompartmental knee arthroplasty (UKA) has been described as an alternative to tibia-first (TF) technique. The aim of this study was to compare the radiographic results in UKAs using FF or TF techniques and their influence on failure rates.
METHODS: We retrospectively reviewed 288 UKAs with a minimum 2-year follow-up. There were 147 knees in the TF and 141 knees in the FF cohorts. Alignment parameters and overhang were assessed as outliers and far outliers. The mean follow-up was 6 years (range, 2 to 16), the mean age was 63 years (range, 27 to 92), and 45% of patients were women. Univariate and multivariate statistical analyses were carried out with Cox regression models.
RESULTS: There were 13 and 6 revisions in the TF and FF cohorts, respectively. The FF had lower rates of femoral coronal alignment (FCA) or femoral sagittal alignment outliers compared to the TF (5.7% versus 19%, P = .011). Tibial coronal alignment and tibial sagittal alignment did not significantly differ between the techniques (22.7% in FF versus 29.9% in TF, P = .119). Overhang outliers did not differ significantly between the groups. Younger age was associated with a higher revision rate (P = .006), while FF versus TF, sex, body mass index, and postoperative mechanical axis did not show statistically significant associations. In multivariate analysis, FCA outliers and younger age were significantly associated with revision.
CONCLUSIONS: The FF technique in mobile-bearing UKA resulted in fewer FCA outliers compared to TF. Despite improved knee alignment with the FF technique, FCA outliers and younger age were associated with a higher revision rate, independent of technique.
Provided is an electronic medical record management method. The method is executed via an electronic medical record management system, and an electronic medical record is written in a carrier held by a patient. The method includes a confirmation medical mechanism write-in permission step, a confirmation write-in carrier wish step, and a write-in step. In the confirmation medical mechanism write-in permission step, the electronic medical record management system receives information related to medical staff and place for performing medical care, and confirms whether the write-in permission is opened. In the confirmation write-in carrier wish step, the electronic medical record management system confirms whether the write-in of the medical record is agreed according to the response or input of the patient. In the write-in step, the electronic medical record is written in the carrier based on the opened write-in permission and the agreement of write-in.
Single dose, dose escalation, vintafolide (Part B) followed by 2 week observation. Those completing Part B will have the option to continue on to Part C (weekly dosing, dose finding, on Days 1, 8, and 15 in a 21-day cycle until disease progression or toxicity) unless they experience severe and/or persistent drug related toxicity.
LINZESS® (linaclotide) 145 μg capsules, orally, once daily for up to 52 weeks for participants with CIC. If an intolerable AE occurred participants could be randomized to the Double-blind Treatment Period.
Experimental: Spironolactone Spironolactone (an aldosterone antagonist) in tablet form taken daily. The initial study drug dose is 25 mg/day (one tablet) and may be titrated up to 50 mg/day (two tablets) within 4 weeks if kidney function at VR was \> 30 mL/min/m2 and potassium \< 4.5 mmol/L.
PURPOSE: To obtain a cosmetic or dermatological powder usable as it is and capable of reconstructing an emulsion. CONSTITUTION: This cosmetic or dermatological powder comprises (A) a structuring and emulsifying agent such as hydrophilic colloid or biopolymer, (b) at least one fatty substance such as a mineral oil (e.g. paraffin oil or vaseline oil), a vegetable oil (e.g. corn oil or olive oil), an animal oil (e.g. animal fat), a fatty acid ester or a fatty alcohol, (C) at least one cosmetic or dermatologically active substance such as pimple preventive, antimicrobial agent or antiperspirant and a water phase and is obtained by hydrating a homogenized oil-in-water type emulsion. The powder comprises 4-30 wt.%, preferably 4-15 wt.% of the component A, 1-94 wt.% of the total of the components B and C and 2-4 wt.% of residual water. A stable oil-in-water type emulsion can be reconstituted by using the powder and adding a liquid in the ratio of the powder/the liquid of 10:1 to 1:1.
PCT No. PCT/US94/05589 Sec. 371 Date Nov. 16, 1995 Sec. 102(e) Date Nov. 16, 1995 PCT Filed May 18, 1994 PCT Pub. No. WO94/26255 PCT Pub. Date Nov. 24, 1994The present invention provides pharmaceutical vaccine compositions that are nanoemulsions of particles having a lipid core which is in a solid or liquid crystalline phase at 25 DEG  C., and which is surrounded by at least one phospholipid bilayer for the parenteral, oral, intranasal, rectal, vaginal or topical delivery of both hydrophilic and lipophilic immunogens. The particles have a mean diameter in the range of 10 to 250 nm and the immunogen is incorporated therein, either intrinsically prior to the homogenization process or extrinsically thereafter.
Compositions and methods for determining endometrial receptivity to embryo implantation and for detecting and treating castration-recurrent prostate cancer are provided. The methods comprise measuring the level of melanoma antigen gene protein-11 (MAGE-11, also referred to as MAGE-Al 1) in an endometrial or prostate tissue sample. The level of MAGE-11 protein or mRNA can be correlated to endometrial receptivity to embryo implantation in a female human or nonhuman primate, or to the presence of castration-recurrent prostate cancer in a male patient in need thereof. Methods are described whereby MAGE-11 may serve as a target for vaccine development in the treatment of castration-recurrent prostate cancer. Methods for monitoring endometrial maturation, for diagnosing infertility, and for in vitro fertilization in a female human or nonhuman primate are also provided. Compositions of the invention include antibodies that specifically bind MAGE-11 and oligonucleotide primers useful for detecting MAGE-11 mRNA, as well as kits containing such antibodies or primers.
The study will be carried out in the department of prosthodontics-cairo university. Patients will be selected from the out-patient clinic according to the inclusion criteria, The primary impression will be made with alginate (cavex-normal set) and will be border-molded to get the acceptable extension and border thickness, a tray will be prepared with self-activated acrylic resin over the study cast. A secondary impression will be made with heavy putty consistency as a border molding material and the final impression will be made with light rubber base (3M) impression material, Then Pouring of the final impressions with type 4 Hydrocal dental stone (Hydrocal Dental stone, Bayer, and Germany). Master casts will be optically scanned using 3 shape optical scanner. Duplication of master casts will be done using silicone duplicating material. Titanium and cobalt/chromium metallic bases will be milled using 3shape milling machine to cover the palate with mesh extension over the ridge. They will be tried intra-orally regarding sitting and stability. Occlusal rim will be set on titanium metallic base then face bow record will be recorded then mounting the maxillary master cast. Centric relation will be registered then mounting of the mandibular cast will be done. The same will be done for the duplicate cast with the Cobalt/Chromium metallic base. Then Setting of the anatomical teeth for both master casts then try-in stage will be checked intra-orally then packing of cast and duplicate cast with conventional heat cured acrylic resin (Dentsply, Dentsply limited, Weybridge, Surrey. England) after flasking each denture will be finished.

The dentures will be delivered, then the assessment will be immediately and after 1 week then after 3 months that a hook screw with its nut (Digital force gauge instrument, model 475044) will be secured in the polished mid-palatal surface of the upper denture using metallic adhesive to record the amount of the force required for dislodgment. The pull end of the digital force gauge device will be connected to the hook positioned at maxillary dentures for one type of the two dentures and will be pulled vertically until denture dislodgement occurred, then the patient will take off his first type of denture for 2 weeks as a washout period then the second type of denture will be delivered and the same assessment will be done.